Bruker Management

Management Kriterienprüfungen 4/4

Bruker's CEO ist Frank Laukien, ernannt in Feb 1991, hat eine Amtszeit von 33.25 Jahren. Die jährliche Gesamtvergütung beträgt $5.86M, bestehend aus 15.8% Gehalt und 84.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 27.68% der Aktien des Unternehmens, im Wert von MX$50.98B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 10.1 Jahre bzw. 8.6 Jahre.

Wichtige Informationen

Frank Laukien

Geschäftsführender

US$5.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	15.8%
Amtszeit als Geschäftsführer	33.3yrs
Eigentum des Geschäftsführers	27.7%
Durchschnittliche Amtszeit des Managements	10.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.6yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Frank Laukien im Vergleich zu den Einnahmen von Bruker verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$402m
Dec 31 2023	US$6m	US$926k	US$427m
Sep 30 2023	n/a	n/a	US$319m
Jun 30 2023	n/a	n/a	US$319m
Mar 31 2023	n/a	n/a	US$312m
Dec 31 2022	US$5m	US$873k	US$297m
Sep 30 2022	n/a	n/a	US$275m
Jun 30 2022	n/a	n/a	US$274m
Mar 31 2022	n/a	n/a	US$282m
Dec 31 2021	US$6m	US$812k	US$277m
Sep 30 2021	n/a	n/a	US$270m
Jun 30 2021	n/a	n/a	US$238m
Mar 31 2021	n/a	n/a	US$204m
Dec 31 2020	US$4m	US$689k	US$158m
Sep 30 2020	n/a	n/a	US$158m
Jun 30 2020	n/a	n/a	US$165m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$753k	US$197m
Sep 30 2019	n/a	n/a	US$207m
Jun 30 2019	n/a	n/a	US$189m
Mar 31 2019	n/a	n/a	US$184m
Dec 31 2018	US$4m	US$731k	US$180m
Sep 30 2018	n/a	n/a	US$98m
Jun 30 2018	n/a	n/a	US$92m
Mar 31 2018	n/a	n/a	US$84m
Dec 31 2017	US$5m	US$704k	US$79m

Vergütung im Vergleich zum Markt: FrankDie Gesamtvergütung ($USD5.86M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt MX ($USD6.01M).

Entschädigung vs. Einkommen: FrankDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Frank Laukien (63 yo)

33.3yrs

Amtszeit

US$5,858,761

Vergütung

Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Frank Laukien	Chairman	33.3yrs	US$5.86m	27.68% $ 51.0b
Gerald Herman	Executive VP & CFO	6.2yrs	US$2.20m	0.029% $ 53.8m
Mark Munch	Corporate Executive VP and President of Bruker Nano Group & Corporate	8.8yrs	US$2.73m	0.048% $ 88.3m
Juergen Srega	President of Bruker CALID Group & Bruker Daltonics Division	11.3yrs	US$1.47m	0.079% $ 145.6m
Falko Busse	President of Bruker BioSpin Group	6yrs	US$1.35m	0.015% $ 27.7m
Justin Ward	Senior Director of Investor Relations & Corporate Development	no data	keine Daten	keine Daten
J. Alldredge	General Counsel & Secretary	no data	keine Daten	keine Daten
Burkhard Prause	President and CEO of Bruker Energy & Supercon Technologies	16.1yrs	US$967.91k	0.0077% $ 14.1m

10.1yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von BRKR * ist erfahren und erfahren (durchschnittliche Amtszeit: 10.1 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Frank Laukien	Chairman	33.3yrs	US$5.86m	27.68% $ 51.0b
John Ornell	Independent Director	8.8yrs	US$241.01k	0.014% $ 26.3m
Robert Rosenthal	Independent Director	8.5yrs	US$224.01k	0.014% $ 26.3m
Richard Packer	Independent Director	17yrs	US$227.32k	0.049% $ 91.1m
William Linton	Independent Lead Director	24.3yrs	US$231.01k	0.023% $ 41.9m
Adelene Perkins	Independent Director	7yrs	US$224.01k	0.013% $ 24.0m
Hermann Requardt	Independent Director	8.8yrs	US$219.01k	0.014% $ 26.3m
Bonnie Anderson	Independent Director	3.7yrs	US$219.65k	0.0053% $ 9.7m
Cynthia Friend	Independent Director	8yrs	US$216.83k	0.0080% $ 14.7m
Philip Ma	Independent Director	2.1yrs	US$206.01k	0.0025% $ 4.5m

8.6yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: BRKR *Die Vorstandsmitglieder gelten als erfahren (8.6 Jahre durchschnittliche Amtszeit).

Bruker Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Bruker Corporation, Annual General Meeting, May 30, 2024

Insufficient new directors

Marc A. Kastner Intends to Retire from as Director of Bruker Corporation

Insufficient new directors

Insufficient new directors

Recent updates

Bruker Corporation Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker Corporation has completed a Follow-on Equity Offering.

Bruker Corporation Announces Quarterly Dividend, Payable on June 17, 2024

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

Bruker Corporation Revises Earnings Guidance for the Year 2024

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation, Annual General Meeting, May 30, 2024

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Fourth quarter dividend of US$0.05 announced

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Full year 2023 earnings released: EPS: US$2.92 (vs US$2.00 in FY 2022)

Insufficient new directors

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Bruker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Bruker Announces SciY Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

Bruker Corporation Announces New D6 PHASER Benchtop X-Ray Diffraction Platform for Materials Analysis and Advanced Research

Bruker CorporationIntroduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments

Bruker Corporation (NasdaqGS:BRKR) announces an Equity Buyback for $500 million worth of its shares.

Bruker Corporation (NasdaqGS:BRKR) acquired ZONTAL, Inc.

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Bruker Corporation Approves Quarterly Dividend, Payable on March 17, 2023

Full year 2022 earnings released: EPS: US$2.00 (vs US$1.83 in FY 2021)

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Bruker Corporation to Report Q4, 2022 Results on Feb 09, 2023

Bruker Corporation Provides Revenue Guidance for the Fourth Quarter of Fiscal Year 2022 and Full Fiscal Year 2023

Bruker Corporation (NasdaqGS:BRKR) acquired Acquifer Imaging Gmbh.

Bruker Corporation (NasdaqGS:BRKR) acquired an unknown majority stake in Biognosys AG.

Bruker Corporation (NasdaqGS:BRKR) acquired Neurescence Inc.

Upcoming dividend of US$0.05 per share

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Neurescence Inc.

Bruker Corporation Announces Quarterly Dividend, Payable on December 16, 2022

Bruker Corporation (NasdaqGS:BRKR) acquired Inscopix, Inc.

Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.57 in 3Q 2021)

Bruker Corporation Provides Earnings Guidance for the Year of 2022

Bruker Corporation to Report Q3, 2022 Results on Nov 03, 2022

Bruker Launches New nanoElute® 2 nano-LC For 4D-Proteomics, Advances Fluxomics Applications with MetaboScape® 2023 Software

Upcoming dividend of US$0.05 per share

Bruker Corporation Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Bruker Approves Payment of Quarterly Cash Dividend, Payable September 16, 2022

Second quarter 2022 earnings released: EPS: US$0.33 (vs US$0.38 in 2Q 2021)

Bruker Corporation Provides Earnings Guidance for the Year 2022

Bruker Corporation to Report Q2, 2022 Results on Aug 03, 2022

Bruker Corporation Launches NMR-Based Molecular Phenomics Clinical Research Tool for ‘Long Covid’ Multi-Organ Risk Assessment

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions At Analytica 2022

Bruker Corporation Introduces Enhanced 3D Holographic Stimulation for Optogenetics on its Ultima 2Pplus Multiphoton Microscope

Bruker Launches timsTOF HT with Greater Dynamic Range for Further Enhancing Unbiased, High-Confidence 4D Proteomics(TM)

Bruker Corporation Announces Quarterly Cash Dividend, Payable on June 17, 2022

Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets

Bruker Corporation (NasdaqGS:BRKR) acquired unknown minority stake in Tofwerk AG for CHF 18 million.

Bruker Demonstrates Novel and Unique Compact 1.0 GHz NMR Magnet

Marc A. Kastner Intends to Retire from as Director of Bruker Corporation

Bruker Corporation to Report Q1, 2022 Results on May 04, 2022

Bruker Corporation (NasdaqGS:BRKR) acquired IonSense, Inc.